On Wednesday, Retrophin Inc (NASDAQ:RTRX)’s shares inclined 5.39% to $23.86.
Retrophin, Inc. (RTRX) declared that Dr. Alvin Shih, Executive Vice President and Head of Research and Development, will present at the Leerink Partners 4th Annual Rare Disease Roundtable in New York City on Wednesday, September 30, 2015 at 8:50 a.m. ET.
Retrophin, Inc., a biopharmaceutical company, focuses on the development, acquisition, and commercialization of therapies for the treatment of serious, catastrophic, or rare diseases. Its product line comprises Cholbam, a cholic acid for the treatment of bile acid synthesis disorders due to single enzyme defects, and for adjunctive treatment of peroxisomal disorders, such as Zellweger spectrum disorders in patients who exhibit manifestations of liver disease, steatorrhea, or complications from reduced fat soluble vitamin absorption; Thiola, which is indicated for the prevention of cystine stone formation in patients with severe homozygous cystinuria with urinary cystine greater than 500 mg/day, who are resistant to treatment with conservative measures of high fluid intake, alkali and diet modification, or who have adverse reactions to d-penicillamine; and Chenodal, a synthetic oral form of chenodeoxycholic acid for radiolucent stones in well-opacifying gallbladders.
Zoetis Inc (NYSE:ZTS)’s shares dropped -1.66% to $44.32.
Zoetis Inc.(ZTS) declared that it has been named among the top ten on Working Mother magazine’s “100 Best Companies for Working Mothers” list for the second successive year. The publication selects the top 100 companies in the U.S. that have demonstrated their commitment to progressive workplace programs such as flexibility, advancement, paid family leave and childcare.
Zoetis ranked highly by Working Mother for its benefits and work-life programs, health and wellness offerings, back-up child care, employee discounts, paid time off, leaves of absence, adoption assistance and tuition aid programs. Zoetis was also acknowledged for its Women’s Council networking group in the U.S., a grass-roots organization of about 500 members who share best practices on issues such as work-life balance and financial planning for families.
Zoetis Inc. engages in the discovery, development, manufacture, and commercialization of animal health medicines and vaccines for livestock and companion animals worldwide. The company operates through four segments: the United States; Europe/Africa/Middle East; Canada/Latin America; and Asia/Pacific.
At the end of Wednesday’s trade, Energy XXI Ltd(NASDAQ:EXXI)‘s shares dipped -6.31% to $1.04.
Energy XXI Ltd (EXXI.L) (the “Company”) declared that it will restate its financial statements to correct its method of accounting for crude oil and natural gas hedging to reflect unrealized hedging gains and losses in the Company’s merged statements of operations as a component of earnings rather than on its merged balance sheets.
Historically, under the cash flow hedge accounting, the Company recorded the unrealized gains and losses on its derivative contracts, net of the related tax impact, in accumulated other comprehensive income or loss as part of the merged balance sheet, until the production month when the associated hedge contracts were settled at which time gains or losses associated with the settled contracts were reclassified to revenues.
Energy XXI (Bermuda) Limited is engaged in the acquisition, exploration, development, production, and operation of oil and natural gas properties onshore in Louisiana and Texas, and on the Gulf of Mexico. A
Antero Resources Corp (NYSE:AR), ended its Wednesday’s trading session with -3.14% loss, and closed at $21.90.
Antero Midstream Partners LP (AM) and Antero Resources Corporation (AR) (“Antero Resources” or the “Company”) jointly declared recently the closing of the formerly declared $1.05 billion water business drop down transaction, private placement of 12,898,000 Antero Midstream common units to a group of institutional investors, and net issuance of 10,988,421 Antero Midstream common units to Antero Resources.
In connection with the $1.05 billion transaction, the Partnership paid Antero Resources $552 million in cash and issued 23,886,421 common units representing limited partner interests in the Partnership to Antero Resources. Additionally, gross proceeds of $243 million from the Partnership’s private issuance of 12,898,000 common units have been paid to Antero Resources while the 23,886,421 of common units issued to Antero Resources has been reduced by the 12,898,000 common units issued in the private placement. Antero Resources now owns 116,870,335 combined common and subordinated units, representing about 66.5% of the outstanding limited partner interests in Antero Midstream.
Antero Resources Corporation, an independent oil and natural gas company, acquires, explores, and develops natural gas, natural gas liquids, and oil properties in the United States. As of December 31, 2014, the company had 543,000 net acres of oil and gas properties located in the Appalachian Basin in West Virginia, Ohio, and Pennsylvania.
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.